Table 3.
The relationship between SPHK1 expression and clinicopathological factors in endometrial carcinoma.
| Clinicopathological factors | Number | SPHK1 expression | χ 2 | P | |
|---|---|---|---|---|---|
| + | − | ||||
| 86 | 69 | 17 | |||
| Age | 0.575 | 0.448 | |||
| <50 years old | 24 | 18 | 6 | ||
| ≥50 years old | 62 | 51 | 11 | ||
| Pathological types | 24.632 | <0.001 | |||
| Adenocarcinoma | 41 | 40 | 1 | ||
| Serous type | 23 | 19 | 4 | ||
| Clear cell type | 13 | 6 | 7 | ||
| Other types | 9 | 4 | 5 | ||
| FIGO staging | 4.463 | 0.035 | |||
| I-II | 63 | 54 | 9 | ||
| III-IV | 23 | 15 | 8 | ||
| Degree of differentiation | 0.556 | 0.757 | |||
| Highly differentiated | 26 | 22 | 4 | ||
| Moderately differentiated | 30 | 23 | 7 | ||
| Poorly differentiated | 30 | 24 | 6 | ||
| Muscle infiltration | 1.316 | 0.251 | |||
| <1/2 | 51 | 43 | 8 | ||
| ≥1/2 | 35 | 26 | 9 | ||
| Lymph node metastasis | 6.657 | 0.010 | |||
| Yes | 58 | 51 | 7 | ||
| No | 28 | 18 | 10 | ||
| ER | 4.986 | 0.026 | |||
| Positive | 30 | 28 | 2 | ||
| Negative | 56 | 41 | 15 | ||
| PR | 6.561 | 0.010 | |||
| Positive | 39 | 36 | 3 | ||
| Negative | 47 | 33 | 14 | ||